Earlier this year the Biden administration made a big bet on small Australian test maker Ellume by giving the company $231m to build a plant in the US to mass produce its at-home over-the-counter antigen tests.
The test received an emergency use authorization (EUA) from the US Food and Drug Administration in December and is touted as a key tool in the government’s arsenal to screen...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?